Infectious Disease Clinical Trial
— A-DONUTOfficial title:
Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection
NCT number | NCT06004739 |
Other study ID # | CTO 4466 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2024 |
Est. completion date | September 2027 |
Delirium is an acute confusional state that is experienced by many older adults who are admitted to hospital. To treat delirium the underlying cause needs to be identified promptly, but this is challenging. One of the potential causes of delirium is infection. Urine tests show that most patients experiencing delirium have bacteria in their urine, however, bacteria in the urine is common among older adults, and does not automatically indicate an infection is present. As a result it is difficult to know whether a lower urinary tract infection is present as individuals with delirium are frequently unable to report clinical signs of infection - symptoms of pain or discomfort with urination, having to urinate more frequently or pelvic discomfort. Very often, individuals with delirium are treated with antibiotics despite the fact that it is unknown whether antibiotics help to improve delirium in cases where bacteria in the urine is present. This proposed study is a randomized controlled trial that will examine if adults (age 60 or older) with delirium and suspected infection benefit from taking antibiotics.
Status | Recruiting |
Enrollment | 550 |
Est. completion date | September 2027 |
Est. primary completion date | September 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion criteria - Age = 60 and admitted to a hospital ward (including rehabilitation hospital); - Active delirium (defined by CAM: [1] inattention AND [2] acute and fluctuating level of consciousness, and either [3] disorganized thinking OR [4] altered mental status; or defined by the 4AT score [www.the4at.com/]) OR physician's diagnosis - Less than 24 hours of antibiotics (prior to trial assessment) - Either pyuria (defined as white blood cells detected on urinalysis or dipstick) or bacteriuria (defined as bacteria growing on urine culture) Exclusion criteria - Fever (temperature > 37.9C or > 100.2F) in the past 48 hours; - Signs of lower urinary tract infection symptoms (such as new dysuria) or upper urinary symptoms (such as costovertebral tenderness) - In the opinion of the treating physician, there is a reason apart from delirium and urine test results to treat with antibiotics (e.g., pneumonia) - Indwelling urinary catheter for > 72 hours |
Country | Name | City | State |
---|---|---|---|
Canada | Sault Area Hospital | Sault Ste. Marie | Ontario |
Lead Sponsor | Collaborator |
---|---|
Mount Sinai Hospital, Canada | Michael Garron Hospital, Sault Area Hospital, The Ottawa Hospital, Unity Health Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Delirium at day 7 or at day of hospital discharge, whichever is earliest | Delirium will be assessed using Confusion Assessment Method (CAM) or 4 A's Test (4AT). CAM assesses 4 delirium features: [1] inattention, [2] acute and fluctuating level of consciousness, [3] disorganized thinking and [4] altered mental status. For a diagnosis of delirium by CAM, the patient must display feature [1] AND [2], AND EITHER [3] or [4]. The 4AT is scored from 0-12. A score of 4 or more suggests delirium. | Delirium will be assessed at the first of day 7 or discharge | |
Secondary | Length of hospitalization | Up to 30 days | ||
Secondary | Number of participants with bacteremia (bacteria isolated in blood culture) | Up to 7 days | ||
Secondary | Number of participants who were transferred to Intensive Care Unit (ICU) | Up to 7 days | ||
Secondary | Number of participants who had a fall | Up to 7 days | ||
Secondary | Number of participants who were physically restrained | Up to 7 days | ||
Secondary | Number of participants who received antipsychotics | Up to 7 days | ||
Secondary | Days of antibiotics | Up to 7 days | ||
Secondary | Number of participants with C. difficile infection | C. difficile will be defined as a combination of a positive microbiological test for C. difficile (if still hospitalized at the time of diagnosis), or self-reported diagnosis of C. difficile (provided the patient reported diarrhea and receipt of an antibiotic to treat C. difficile) | By 30 days | |
Secondary | Number of participants who died | By 30 days | ||
Secondary | Number of participants who died | By 365 days | ||
Secondary | Number of participants who were readmitted to hospital | By 365 days | ||
Secondary | Number of participants who were readmitted to hospital | By 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05568953 -
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
|
Phase 2 | |
Completed |
NCT04568889 -
Minnesota COVID-19 Testing Project
|
N/A | |
Completed |
NCT06063330 -
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
|
Phase 1 | |
Completed |
NCT01198925 -
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
|
Phase 4 | |
Completed |
NCT05063812 -
Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
|
||
Not yet recruiting |
NCT03636711 -
Antibiotic Stewardship in Infectious Disease Departement
|
||
Completed |
NCT03457688 -
Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children
|
N/A | |
Completed |
NCT03241355 -
Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children
|
N/A | |
Terminated |
NCT05420077 -
Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273
|
Phase 1 | |
Completed |
NCT04084106 -
Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota
|
Phase 4 | |
Recruiting |
NCT05013944 -
AnovaOS Network Powered Patient Registry
|
||
Completed |
NCT03893279 -
Perception of Smell and Taste During Antibiotic Treatment
|
||
Active, not recruiting |
NCT05619770 -
Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
|
Phase 1 | |
Completed |
NCT01772901 -
Brief Influenza Vaccine Education to Pregnant Women
|
N/A | |
Completed |
NCT05413772 -
Temocillin in ESBL-Enterobacteriaceae Infections
|
||
Completed |
NCT04319328 -
Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
|
||
Completed |
NCT04613271 -
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
|
Phase 3 | |
Completed |
NCT03239665 -
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
|
N/A | |
Completed |
NCT03224026 -
Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source
|
||
Not yet recruiting |
NCT06102070 -
Genetic Susceptibility to Severe Infections
|